Azevedo, Maria Luíza SchaeferRezende, Giselle A. S.Sousa, Lucas Resende DutraReis, Rúbia Castro Fernandes MeloNovack, Kátia MonteiroBarboza, Ana Paula MoreiraNeves, Bernardo Ruegger AlmeidaAmparo, Tatiane RoqueteTeixeira, Luiz Fernando de MedeirosVieira, Paula Melo de AbreuPerasoli, Fernanda BarçanteSantos, Viviane Martins Rebello dos2023-01-262023-01-262022AZEVEDO, M. L. S. et al. New studies in vitro antibacterial evaluation and cell viability in PMMA-G-PEG 4000 derivatives with encapsulated Erythromycin. Revista Virtual de Quimica, v. 14, n. 5, p. 814-818, 2022. Disponível em: <https://rvq-sub.sbq.org.br/index.php/rvq/article/view/4267>. Acesso em: 11 out. 2022.1984-6835http://www.repositorio.ufop.br/jspui/handle/123456789/16054Synthetic polymers have been extensively studied in several areas of knowledge, one of which is the pharmaceutical. The drug when encapsultated into the PMMA-g-PEG 4000 matrix can produce fewer side effects. The most frequent side effects of erythromycin are gastrointestinal and are dose related. Nausea, vomiting and diarrhea occur in low frequency with the usual oral doses. The drug used in this study was Erythromycin, an antimicrobial that acts directly on bacterial protein synthesis. Erythromycin was encapsulated into PMMA-g-PEG 4000 derivatives. All copolymers afther encapsultaions were characterized and identified by atomic force microscopy (AFM). In vitro assays of release, antimicrobial activity and cytotoxicity were performed for the copolymers obtained. The copolymers PMMA-g-PEG 4000 HAL and PMMA-g-PEG 4000 ACET showed drug controlled release profiles. All PMMA-g-PEG 4000 derivatives showed antibacterial activity against Staphylococcus aureus and did not show a cytotoxic effect on human fibroblasts.en-USabertoCopolymersControlled releaseAntibacterial activityArtigo publicado em periodicoThis is an open-access article distributed under the terms of the Creative Commons Attribution License. Fonte: o PDF do artigo.https://doi.org/10.21577/1984-6835.20220037